The global Gene Expression Market, valued at USD 11.5 billion in 2022, is projected to experience a rapid compound annual growth rate (CAGR) of 10% throughout the forecast period. The driving forces behind this upward revenue trajectory include the escalating prevalence of chronic ailments such as cancer, cardiovascular diseases (CVDs), and neurological disorders, coupled with the expanding role of gene expression in drug discovery. Gene expression, a technique that employs genetic instructions to synthesize gene products, has facilitated the exploration of individual genes at the molecular level. Technological advancements have ushered in more sophisticated methods for gene expression analysis, considerably enhancing the accuracy and reliability of this analysis.
Researchers heavily depend on gene expression analysis techniques to identify and validate pharmacological targets, predict treatment effectiveness, and assess safety profiles. These techniques are vital for pinpointing genetic variances that might influence a patient's response to a particular treatment. The concept of personalized medicine, which tailors treatments based on an individual's genetic makeup, hinges on the insights provided by gene expression analysis.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/1474
The adoption of Next-Generation Sequencing (NGS) technologies is expected to be a pivotal driver of market growth. NGS technologies enable rapid and precise sequencing of large volumes of genomic material, leading to a deeper comprehension of gene expression and its mechanisms. Additionally, the proliferation of publicly accessible databases containing gene expression data equips researchers with abundant information for analysis and interpretation.
Nevertheless, challenges such as the intricate nature of data analysis and interpretation, the high costs associated with gene expression analysis instruments, and the absence of standardized data analysis and reporting protocols could impede revenue growth. Intense competition within the industry, stemming from numerous companies offering diverse tools and services for gene expression analysis, is another potential restraint.
Regulatory Framework: The U.S. Food and Drug Administration (FDA) classifies gene expression products as medical devices under its Medical Device Regulation Program (MDRP). The European Commission has enacted the General Product Safety Directive (GPSD), necessitating safety information provision before gene expression products can be marketed in the European Union (EU). Certain gene expression products require clinical data to demonstrate safety and effectiveness, as stipulated by the FDA. The U.S. Centers for Medicare Medicaid Services (CMS) regulates gene expression tests conducted in clinical settings through the Clinical Laboratory Improvement Amendments (CLIA). FDA guidelines encompass aspects such as sample collection, storage and labeling, record-keeping, and quality assurance for gene expression products. These guidelines ensure accurate and reliable test results.
Key Insights:
Product Type Analysis: The global gene expression market is divided into consumables and instruments. Consumables, including reagents, kits, and chemical substances essential for gene expression analysis, accounted for the largest share of revenue in 2022. This growth was propelled by escalating demand for gene expression analysis in research and development activities. The launch of novel technologies and products is anticipated to further augment revenue in this segment.
The instruments segment is poised to witness a steady growth rate in the global gene expression market. Tools such as PCR machines and microarray scanners play a crucial role in executing studies and evaluating gene expression data. Demand for automated high-throughput analysis systems, delivering quicker and more accurate results, is expected to drive this segment's growth.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/1474
Technique Breakdown: Based on technique, the market is categorized into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), microarray, and others. PCR experienced the fastest revenue growth in 2022, attributed to the rising need for accurate identification of genetic abnormalities and infectious diseases. Advanced PCR technologies like real-time PCR and multiplex PCR are also expected to contribute to this growth.
NGS is projected to claim a substantial revenue share due to increasing demand for precise and affordable sequencing technologies, along with the declining cost of NGS sequencing. Microarray techniques are predicted to see moderate growth, driven by the demand for gene expression profiling and diagnostics.
Regional Landscape: In 2022, the Asia Pacific region led in revenue share owing to robust demand from countries such as China and India, alongside access to reasonably priced high-quality gene expression products. The region's burgeoning biotechnology sector, particularly in China, is set to fuel market growth.
North America is anticipated to experience the fastest revenue growth due to well-developed healthcare infrastructure and the utilization of precision medicine. The region's adoption of advanced gene editing techniques like CRISPR-Cas9 and the prevalence of chronic diseases will further contribute to revenue expansion.
Europe is projected to hold a substantial revenue share due to the growing demand for precision medicine and personalized healthcare. Furthermore, the use of gene expression in the Food Beverage sector, particularly in Germany and France, is expected to drive growth.
Competitive Landscape: The gene expression market is fiercely competitive, with several large and mid-sized players dominating the revenue share. To maintain their edge, these companies employ strategies like mergers, acquisitions, partnerships, collaborations, and product launches. Key players include Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation, Takara Bio Inc., Promega Corporation, and GeneCopoeia, Inc.
Strategic Developments: Illumina, Inc. acquired Grail, a leading healthcare company specializing in blood-based cancer detection tests, for USD 8 billion on August 18, 2021. This move aimed to bolster Illumina's position in the liquid biopsy market and advance its gene expression profiling tools. Thermo Fisher Scientific Inc. acquired contract research organization PPD for USD 17.4 billion on April 15, 2021. This acquisition aimed to enhance Thermo Fisher's presence in the clinical research market, including gene expression studies. Agilent Technologies, Inc. acquired BioTek Instruments, a provider of life science instrumentation, for USD 1.2 billion on August 27, 2019. This strategic move bolstered Agilent's capabilities in cell analysis and fortified its gene expression product portfolio.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/1474
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Bullous Pemphigoid Treatment Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
